Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin

References

• Kim YH, Liu HL, Mraz-Gernhard S, . Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857–866.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Gan S, Jones J, . Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006;107:2504–2511.
   PubMed Web of Science ®Google Scholar
• Meyer N, Paul C, Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol 2010;90:12–17.
   PubMed Web of Science ®Google Scholar
• Pujol RM, Gallardo F, Llistosella E, . Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol 2002;47:S168–S171.
   PubMedGoogle Scholar
• Bowen GM, Stevens SR, Dubin HV, . Diagnosis of Sezary syndrome in a patient with generalized pruritus based on early molecular study and flow cytometry. J Am Acad Dermatol 1995;33:678–680.
   PubMed Web of Science ®Google Scholar
• Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012;51:930–934.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1485–1507.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 2005;141:325–330.
   PubMed Web of Science ®Google Scholar
• Whittaker S, Demierre M, Kim EJ, . Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27: 5410–5417.
   PubMed Web of Science ®Google Scholar
• Whittaker S, Frye R, Nichols J, . Complete responses with romidepsin in cutaneous T-cell lymphoma (CTCL) studies. Poster presented at First World Congress of Cutaneous Lymphomas. 22–25 September 2010. Chicago, IL.
   Google Scholar
• Lundin J, Hagberg H, Repp R, . Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267–4272.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A, . Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376–388.
   PubMed Web of Science ®Google Scholar
• Edelson R, Berger C, Gasparro F, . Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316:297–303.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–39.
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, . Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28:1870–1877.
   PubMed Web of Science ®Google Scholar
• Stratford PW, Binkley JM, Riddle DL, . Sensitivity to change of the Roland-Morris back pain questionnaire: part 1. Phys Ther 1998;78:1186–1196.
   PubMed Web of Science ®Google Scholar
• Copay AG, Subach BR, Glassman SD, . Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541–546.
   PubMed Web of Science ®Google Scholar
• DeLoach LJ, Higgins MS, Caplan AB, . The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102–106.
   PubMed Web of Science ®Google Scholar
• Revill SI, Robinson JO, Rosen M, . The reliability of a linear analogue for evaluating pain. Anaesthesia 1976;31:1191–1198.
   PubMed Web of Science ®Google Scholar
• Campbell WI, Patterson CC. Quantifying meaningful changes in pain. Anaesthesia 1998;53:121–125.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research; US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
   PubMed Web of Science ®Google Scholar
• Wagner L, Zaluda L, Guitard J, . Health-related quality of life among patients with cutaneous lymphoma: development of the functional assessment of cancer therapy – cutaneous lymphoma (FACT-CTCL). Oral presented at First World Congress of Cutaneous Lymphomas. 22–25 September 2010. Chicago, IL.
   Google Scholar
• Desai NS, Poindexter GB, Monthrope YM, . A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59:234–244.
   PubMed Web of Science ®Google Scholar
• Chen SC, Nguyen L, Pugliese S, . Pruritus in cutaneous T-cell lymphoma patients: prevalence and quality of life impact. Oral presented at First World Congress of Cutaneous Lymphomas. 22–25 September 2010. Chicago, IL.
   Google Scholar
• Chen SC, Nguyen L, Pugliese S, . Quality of life impact by cutaneous T-cell lymphoma: results from existing instruments. Oral presented at First World Congress of Cutaneous Lymphomas. 22–25 September 2010. Chicago, IL.
   Google Scholar
• Chen SC, Nguyen L, Pugliese S, . Quality of life impact by cutaneous T-cell lymphoma: current instruments may not be sufficient. Oral presented at First World Congress of Cutaneous Lymphomas. 22–25 September 2010. Chicago, IL.
   Google Scholar